MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AARD had $13,287K increase in cash & cash equivalents over the period. -$16,134K in free cash flow.

Cash Flow Overview

Change in Cash
$13,287K
Free Cash flow
-$16,134K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-16,316 -23,677
Credit loss - related party accounts receivable
0 0
Stock-based compensation expense
1,500 867
Non-cash lease expense
83 213
Unrealized (gain) loss on short-term investments
36 -22
Amortization of discount on short-term investments
372 701
Depreciation expense
10 16
Prepaid expenses and other assets
1,313 4,278
Accounts payable
-612 3,223
Accrued liabilities
1,026 3,217
Operating lease liability
-100 -134
Net cash used in operating activities
-16,130 -21,232
Purchases of short-term investments
0 124,651
Maturities/sales of short-term investments
29,250 21,527
Purchases of property and equipment
4 91
Net cash used in investing activities
29,246 -103,215
Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts
0 91,075
Financing costs paid in connection with issuance
0 2,387
Proceeds from sale and issuance of series c convertible preferred stock
0 0
Financing costs paid in connection with issuance of series c convertible preferred stock
0 0
Proceeds from exercises of common stock options
171 116
Net cash provided by financing activities
171 88,804
Net (decrease) increase in cash and cash equivalents
13,287 -35,643
Cash and cash equivalents at beginning of period
61,641 -
Cash and cash equivalents at end of period
39,285 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics, Inc. (AARD)